View Full Paper

Owner Consent Verified
Report 4.8

Impact Investing for Pharmaceutical Firms: Resilience And Continuity | A difference-in-differences analysis

7
Pages
IEEE
Style
~ 7–11 mins
Reading Time
RPA BioMed AIOps
Abstract

This report investigates “Impact Investing for Pharmaceutical Firms: Resilience And Continuity | A difference-in-differences analysis” using a panel regression with fixed effects. Through a behavioral lens, the analysis integrates multi-source data to derive novel empirical evidence for researchers and practitioners.

Download PDF Order Similar Paper Save

Impact Investing for Pharmaceutical Firms: Resilience And Continuity | A difference-in-differences analysis

ABSTRACT
Impact Investing for Pharmaceutical Firms: Resilience And Continuity | A difference-in-differences analysis is unpacked across themes: usability, costs, KPIs, and benefits. Limitations and future research paths are noted.
1
Open full preview
Related Papers
Browse all
16 Pages 4.9
Hospitality Management Adoption in EU Startups: Resilience And Continuity — 2023–2027 Trends
Data Privacy Health HCI
View Paper
38 Pages 4.8
Renewable Energy and Change Management among Esports Organizations — A design science research
MLOps Sociology AIOps
View Paper
40 Pages 4.6
Human Factors And Usability in 5G Networks for Fortune 500 Firms: 2021–2029 Trends
Open Banking AI Governance
View Paper